The United Kingdom and the United States have reached a important trade agreement that will guarantee zero import taxes on UK drug exports going into the American market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has committed to increase expenditure on medicines through the public health system. This move guarantees that duties on these vital goods will be held at nothing for a duration of three years.
This development comes after previous warnings to dramatically increase tariffs on patented drug products, with increases discussed as high as double the cost.
"This arrangement with the United Kingdom bolsters the worldwide climate for innovative medicines and establishes much-needed equity to U.S.–U.K. pharmaceutical trade," a release declared.
Commercial Significance
Medicines represent one of the UK's biggest exports to the United States, which is by far the largest buyer for major companies like GSK and AstraZeneca.
Export figures show that in the one-year period to the end of the third quarter, the UK shipped medicines worth billions to the US. This amount accounted for nearly one-fifth of all goods exports in that timeframe.
"This guarantee safeguards employment, stimulates investment and paves the way for the UK to emerge as a worldwide center for biotech and pharma," the Business and Trade Secretary commented.
Key UK Commitments
The pact includes several notable pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it considers new therapies to be too expensive by a quarter.
- Increased NHS Spending: There is a target to increase total public funding on drugs from 0.3% of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The percentage manufacturers must refund to the NHS to stay within budget will be capped at fifteen percent. In the past, repayments were more than twenty percent.
Recent Tensions
The deal follows a long-running dispute between the pharmaceutical industry and the British authorities over medicine costs and NHS adoption.
These tensions were exacerbated by arguments that American patients were charged several times more for the same drugs than people in the Britain and the EU.
Recently, several major manufacturing plans in the UK have been paused or scrapped, while substantial funding commitments have been announced toward American operations.
A senior figure stated that the NHS must increase expenditure on drugs, noting that its budget allocation on drugs had decreased as a percentage of its total funding over the previous ten-year period.
